| __timestamp | Jazz Pharmaceuticals plc | Neurocrine Biosciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 406114000 | 17986000 |
| Thursday, January 1, 2015 | 449119000 | 32480000 |
| Friday, January 1, 2016 | 502892000 | 68081000 |
| Sunday, January 1, 2017 | 544156000 | 169906000 |
| Monday, January 1, 2018 | 683530000 | 248932000 |
| Tuesday, January 1, 2019 | 736942000 | 354100000 |
| Wednesday, January 1, 2020 | 854233000 | 433300000 |
| Friday, January 1, 2021 | 1451683000 | 583300000 |
| Saturday, January 1, 2022 | 1416967000 | 752700000 |
| Sunday, January 1, 2023 | 1343105000 | 887600000 |
| Monday, January 1, 2024 | 1007200000 |
Unveiling the hidden dimensions of data
In the competitive landscape of biopharmaceuticals, operational efficiency is paramount. Over the past decade, from 2014 to 2023, Jazz Pharmaceuticals and Neurocrine Biosciences have showcased distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. Jazz Pharmaceuticals, with a consistent upward trend, saw its SG&A expenses grow by approximately 230%, peaking in 2021. This reflects their aggressive expansion and market penetration strategies. In contrast, Neurocrine Biosciences, starting from a modest base, experienced a staggering increase of nearly 4,800% in SG&A expenses, highlighting their rapid growth and scaling efforts. By 2023, Neurocrine's SG&A expenses reached 66% of Jazz's, a significant leap from just 4% in 2014. This analysis underscores the dynamic shifts in operational strategies within the biopharmaceutical sector, offering insights into how these companies allocate resources to drive growth and innovation.
Who Optimizes SG&A Costs Better? Sanofi or Neurocrine Biosciences, Inc.
Operational Costs Compared: SG&A Analysis of Regeneron Pharmaceuticals, Inc. and Neurocrine Biosciences, Inc.
Cost Management Insights: SG&A Expenses for BeiGene, Ltd. and Neurocrine Biosciences, Inc.
Comparing SG&A Expenses: Neurocrine Biosciences, Inc. vs Catalent, Inc. Trends and Insights
Neurocrine Biosciences, Inc. vs Bio-Techne Corporation: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and CRISPR Therapeutics AG
Breaking Down SG&A Expenses: Neurocrine Biosciences, Inc. vs Rhythm Pharmaceuticals, Inc.
Neurocrine Biosciences, Inc. and Mesoblast Limited: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Neurocrine Biosciences, Inc. vs Novavax, Inc.
Walgreens Boots Alliance, Inc. and Jazz Pharmaceuticals plc: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? Jazz Pharmaceuticals plc or CymaBay Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Jazz Pharmaceuticals plc and Arrowhead Pharmaceuticals, Inc.